Treatment with the NLRP3-dependent procaspase 1, IL-1β, and the IL-18 inhibitor Fclla-2 can reduce colon inflammation in mice [10], and the NLRP3 inflammasome can initiate and promote the inflammatory response in colitis [11]. This evidence concerns the gene NLRP3 and colitis.